QIAGEN reported strong Q3 2026 financial results, exceeding revenue expectations, but simultaneously suspended its full-year guidance due to a pending acquisition offer from EQT Private Equity. This dual announcement presents a complex picture for investors, highlighting both operational strength and an imminent corporate change.
QIAGEN's Q3 2026 results show a 2.8% revenue increase and improved adjusted EPS, indicating solid operational performance. However, the suspension of 2026 guidance due to EQT's €46.50 per share acquisition offer overshadows these results, shifting investor focus from fundamentals to the M&A transaction. This is a major corporate catalyst, as the company's future is now tied to the success of the acquisition. Shareholders will be evaluating the offer price against the company's intrinsic value and growth prospects. The increased stake by BlackRock suggests institutional confidence, potentially in the acquisition's success or the company's underlying value, but the immediate impact for traders is the arbitrage opportunity or the risk of the deal falling through.